Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

Dow Jones Top Company Headlines at 11 AM ET: Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera | Mounjaro ... Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Eli Lilly chairman and CEO David Ricks joins CNBC’s “Squawk on the Street” team to discuss its quarterly earnings report that ...

Eli Lilly shares surged after strong third-quarter results and a raised annual forecast, powered by booming demand for its ...

Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong international demand for weight-loss drugs ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

Dow Jones Top Company Headlines at 9 AM ET: Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings | Novo ... Eli Lilly reported higher profit and raised its outlook on surging demand for its ...

Eli Lilly stock jumped early Thursday after the drugmaker easily topped third-quarter forecasts on the back of its two ...

Eli Lilly reported higher profit and raised its outlook on the back of surging demand for its weight-loss drugs, sending its ...

Eli Lilly raised its full-year profit and revenue forecast on Thursday as strong appetite for its widely popular weight-loss ...